Nuvation Bio director granted 123,397 stock options

Nuvation Bio Inc. director Robert B. Bazemore received a stock option grant covering 123,397 shares of Class A common stock.

Rhea-AI Filing Summary

Nuvation Bio Inc. director Robert B. Bazemore received a stock option grant covering 123,397 shares of Class A common stock. The option has an exercise price of $4.79 per share and expires on May 20, 2036. All shares vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, subject to his continuous service. This is a compensation-related award, with no open-market share purchases or sales reported.

Insider Trade Summary

Grant/Award: 123,397 shares

Grant/Award 1 txn

Insider Bazemore Robert B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	123,397	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 123,397 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Key Figures

Option grant size: 123,397 shares Exercise price: $4.79 per share Shares underlying option: 123,397 shares +3 more

6 metrics

Option grant size 123,397 shares Stock Option (Right to Buy) granted to director

Exercise price $4.79 per share Exercise price of stock option

Shares underlying option 123,397 shares Class A Common Stock underlying the option

Expiration date May 20, 2036 Option expiration

Vesting date trigger May 21, 2026 or next annual meeting 100% vesting, subject to continuous service

Post-transaction derivative holdings 123,397 options Total options held after this grant

Key Terms

Stock Option (Right to Buy), Class A Common Stock, Grant, award, or other acquisition, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.7900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service through such applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) report for Robert B. Bazemore?

Nuvation Bio reported a stock option grant to director Robert B. Bazemore. He received options for 123,397 shares of Class A common stock as a compensation-related award, not an open-market purchase or sale.

How many Nuvation Bio (NUVB) shares are covered by Bazemore’s new stock option?

The stock option granted to Robert B. Bazemore covers 123,397 shares. These options give him the right to buy that number of Class A common shares if he chooses to exercise them after they vest.

What is the exercise price and expiration date of Bazemore’s NUVB option grant?

The option has an exercise price of $4.79 per share and expires on May 20, 2036. This means Bazemore can buy shares at $4.79 anytime before the expiration, once the option is vested.

When do Robert B. Bazemore’s Nuvation Bio (NUVB) options vest?

All 123,397 option shares vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting. Vesting is conditional on Bazemore’s continuous service with Nuvation Bio through the applicable vesting date.

Did Robert B. Bazemore buy or sell any NUVB shares in this Form 4?

The Form 4 reports only a stock option grant to Robert B. Bazemore. It does not show any open-market purchases or sales of Nuvation Bio Class A common stock by him in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 08:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bazemore Robert B

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.79	05/21/2026		A		123,397		(1)	05/20/2036	Class A Common Stock	123,397	$0	123,397	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)